Guggenheim Initiates Coverage On Faeth Therapeutics with Buy Rating, Announces Price Target of $70

Benzinga Newsdesk www.benzinga.com Positive 53.6%

Neg 0% Neu 0% Pos 53.6%

Guggenheim analyst Brad Canino initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Buy rating and announces Price Target of $70.